Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?
about
The Community Liaison Program: a health education pilot program to increase minority awareness of HIV and acceptance of HIV vaccine trialsEnrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge.Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical preventionHIV vaccine trial preparedness among Spanish-speaking Latinos in the US.HIV vaccine acceptability among communities at risk: the impact of vaccine characteristicsIn "Step" with HIV Vaccines? A Content Analysis of Local Recruitment Campaigns for an International HIV Vaccine StudyCost-effectiveness of male circumcision for HIV prevention in a South African setting.Sexual risk behavior has decreased among men who have sex with men in Los Angeles but remains greater than that among heterosexual men and women.Willingness to participate in HIV vaccine trials: the impact of trial attributes.HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approachHIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study.The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention.Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, TanzaniaLong-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial.Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICESEnrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine.Exploring decision-making of HIV-infected Hispanics and African Americans participating in clinical trialsEngaging members of African American and Latino communities in preventive HIV vaccine trials.Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences.From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South AfricaPredicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial.Anticipated changes in sexual risk behaviour following vaccination with a low-efficacy HIV vaccine: survey results from a South African township.What can HIV vaccine trials teach us about future HIV vaccine dissemination?Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES).Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback.A small dose of HIV? HIV vaccine mental models and risk communication.Assessing the interest to participate in a dengue vaccine efficacy trial among residents of Puerto Rico.If We Build It, Will They Come? Perceptions of HIV Cure-Related Research by People Living with HIV in Four U.S. Cities - A Qualitative Focus Group Study.Risk, individual differences, and environment: an Agent-Based Modeling approach to sexual risk-taking.HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada.Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study.Acceptability and Preferences for Hypothetical Rectal Microbicides among a Community Sample of Young Men Who Have Sex with Men and Transgender Women in Thailand: A Discrete Choice Experiment.'Why would you promote something that is less percent safer than a condom?': Perspectives on partially effective HIV prevention technologies among key populations in South AfricaA social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand
P2860
Q24597056-1F1276F2-132B-4C62-95BA-4F3A84FA1785Q25255907-89540ADD-AD66-4AAE-AAD4-E032579F859CQ30206105-CB0B9F63-1AF6-4289-8B33-0B482F92007BQ30230248-8D7D8392-E086-496B-9DDC-F1D42BF7BA34Q30352116-959498C5-2BED-4FFF-9512-0BC56CF5AC0CQ30378981-6A846AA9-9F87-466D-9B22-899C71EEA07EQ33267835-3DE212E1-F50A-49CB-B94D-3029FCC0D789Q33641467-CDFA67F9-B8E6-418F-8418-C35AB617AF6BQ33643631-EC59AEDD-0BC8-4C7A-AA60-331DF9AB9C48Q33689222-1D7EA632-42E5-47DC-9CB9-0FF16B0CD8CFQ33786360-17B402D6-D39A-4E0B-A97B-0A7ED6BBBA1BQ33828458-996F7A06-6D47-461F-B7FB-EC9EDFE7A0A1Q33831829-69478CC9-642D-4BB9-9C7F-F112CE685651Q33987449-F273F21D-33A8-42D6-AF85-E365979DE113Q34063486-22CD90A9-8314-4740-8BF8-709C46AEDD53Q34159806-299F75E0-E944-4A59-99DB-5CACD3692FCAQ34990295-9CB3D77B-F381-4BD0-93D4-32A558B359A5Q35736408-C9E684AD-A91E-42CA-A58E-AA0229AA9D48Q36022717-8513A8AC-EE85-4879-A5F6-419DFA469708Q36272757-8242AB94-0C50-419A-A7AD-D3F07AB77E17Q36603971-CBCD3D23-3514-4DF6-A1AB-59ABBCF61818Q36853358-88A2F39F-F2C6-4C79-A09F-F5F1220B70B7Q36975561-EE3C8FFF-7CB5-4030-9E4C-E0048F260B2CQ37274924-4E369A09-F900-47C5-AC5E-5B6270BAAAB1Q37485276-7CC152A0-A639-49EE-8B87-53723B1AF2C9Q40123390-837A4E5D-BDFA-4617-81A8-C8699E27C07CQ40151338-EABD4D49-1E29-4B87-A667-6FCD31920CB1Q40279553-791FB71B-138B-4DD0-987C-841AD7CC4B10Q46503488-059F2F72-D6B9-4BB0-B349-13FD91F2E128Q48032830-99A67473-F190-4161-8CC8-0D31FCBE825FQ48149128-5B785FE1-3DDB-4112-9E2F-8C61D4ADA911Q50114646-8D698D4E-9BF1-4BAD-AFCB-A66EDF2C68E4Q50135709-78B45FFD-E7BA-4D9C-A2FA-D7C4E24EFCE6Q58452343-5B8AF655-5FDE-4C4B-B27A-A63E9B7E3709Q58452373-EEF35BC9-15C8-4652-812C-133814F7CE1E
P2860
Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Challenges for HIV vaccine dis ...... f we build it, will they come?
@ast
Challenges for HIV vaccine dis ...... f we build it, will they come?
@en
type
label
Challenges for HIV vaccine dis ...... f we build it, will they come?
@ast
Challenges for HIV vaccine dis ...... f we build it, will they come?
@en
prefLabel
Challenges for HIV vaccine dis ...... f we build it, will they come?
@ast
Challenges for HIV vaccine dis ...... f we build it, will they come?
@en
P2093
P356
P1476
Challenges for HIV vaccine dis ...... f we build it, will they come?
@en
P2093
Ellen T Rudy
Naihua Duan
Peter A Anton
P304
P356
10.1089/APC.2004.18.691
P577
2004-12-01T00:00:00Z